Introduction {#sec1-1}
============

Primary sub-diaphragmatic pediatric Hodgkin lymphoma (HL) comprises merely 3% of all pediatric cases.\[[@ref1]\] Isolated HL in the pelvis is rarely reported.\[[@ref2][@ref3]\] We report a prepubertal girl with a pelvic mass, which uniquely turned out to be HL. Besides chemotherapy, the management involved debating pros and cons of administering radiotherapy to the sensitive site.

Case Report {#sec1-2}
===========

An 11-year-old girl presented with fever for 4 months. On examination, a left-sided suprapubic mass was palpated. Ultrasonography confirmed a mass in the pelvis. A magnetic resonance imaging revealed a large mass located in the pelvis, along with enlarged lymph nodes \[[Figure 1](#F1){ref-type="fig"}\]. The initial clinical possibility was of a gonadal germ cell tumor. Serum alpha-fetoprotein and beta-human chorionic gonadotrophin were normal. A core biopsy was consistent with a diagnosis of HL, nodular sclerosis (NS) type. Immunohistochemistry was confirmatory; the large atypical cells were positive for CD15/CD30 and negative for CD20. An 18-fluorodeoxyglucose-positron emission tomography-computed tomography (FDG-PET-CT) confirmed FDG avidity of the mass and adjoining nodes. The bone marrow was not infiltrated.

![Magnetic resonance imaging (a - sagittal view, b - coronal view) demonstrated a large pelvic mass (arrows in a and b). The left sided ovary was not distinctly identified. The uterus and urinary bladder were displaced and compressed by the mass](IJMPO-38-226-g001){#F1}

The patient was assigned to stage IIB and treatment - Group-2 of the Euronet-Paediatric Hodgkin\'s Lymphoma Group protocol (EuroNet-PHL-C1).\[[@ref4]\] Two cycles of O-vincristine, E-etoposide, P-prednisone, A-adriamycin were administered. An interim FDG-PET-CT revealed \>50% reduction of the mass, with a Deauville score (DS) of three, with complete resolution of the nodes. As per the guidelines of EuroNet-PHL-C1 trial, with a local partial remission and a DS of three, radiotherapy was indicated following two cycles of C-cyclophosphamide, O-vincristine, P-prednisone, DAC-dacarbazine (COPDAC). However, there was a major concern for infertility with radiotherapy to the pelvis. The multi-disciplinary team, along with the parents debated the options. The emerging international consensus was of DS of 1--3 being considered as a complete metabolic response at early interim PET.\[[@ref5]\] Indeed, in the succeeding Euronet-C2 trial, the threshold of radiotherapy was to be raised to DS of 4--5, instead of 3--5.\[[@ref6]\] The team opted to avoid radiotherapy and administer two additional (total: four) cycles of COPDAC, instead. An ultrasonography performed following six cycles of chemotherapy revealed a small cystic residual mass in the region of the left adenexa. A diagnostic laparoscopy performed to visualize and biopsy the mass demonstrated trivial bogginess of soft tissue in the pelvic wall with no visible mass. She has been well and in follow-up for 18 months.

Discussion {#sec1-3}
==========

Primary infradiaphragmatic HL has been reported in 4%--13% of patients in studies encompassing all age groups.\[[@ref7][@ref8]\] Published literature on isolated pelvic disease is restricted to adults.\[[@ref2][@ref3]\] Infradiaphragmatic HL demonstrates distinct characteristics when compared to supradiaphragmatic disease such as older age, multiple involved sites, increased frequency of lymphocyte predominant histology, and a reduced frequency of NS variants.\[[@ref7][@ref8][@ref9][@ref10]\] Survival rates are not observed to be different, and recommendations for treatment do not differ.\[[@ref4][@ref7][@ref8][@ref9]\] Bulky disease with an inadequate response on interim FDG-PET is ideally radiated, albeit with increased risk of gonadal failure, premature menopause, and infertility in pelvic HL.\[[@ref11]\] According to the Lugano classification for the management of lymphomas, DS-3 on interim FDG-PET indicates a favorable prognosis in most patients; interpretation must take into account timing of assessment, clinical context, and treatment.\[[@ref5]\] We consciously avoided radiotherapy and administered two additional cycles of chemotherapy to avoid gonadal failure. A longer follow-up is necessary for ensuring a relapse-free period.

Conclusions {#sec1-4}
===========

Pelvic HL is a rarity in children. The decision for radiotherapy is arduous due to the risk of infertility.
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